●  First biological product launched in 1999

●  3 products launched, 2 have the largest market share in China

●  Focusing on research and commercialization of recombinant protein drugs

 from prokaryotic expression and mammalian cell expression

●  Robust pipeline comprising biosimilars and innovative biologics

●  Manufacturing facilities complying with cGMP requirements

●  Dosage forms: ampoules, vials, pre-filled syringes, etc

Qilu Biopharmaceutical Industrial Park 

●  Total construction area covers 800,000 m2

●  Being constructed in accordance with the requirements of USFDA cGMP/EU GMP

●  Phase I construction completed and manufacture commenced. Manufacturing facilities are available for production of:

   - Mammalian cell expression products
   - Prokaryotic cell expression products
   - Small molecule finished formulations